Safety of Palivizumab Stewardship in Conjunction with Infection Prevention and Control Strategies for Healthcare-Associated Respiratory Syncytial Virus Infections

Rupal M. Patel*, Larry K. Kociolek, Emily Merrick, Caroline Reuter, Kenny Kronforst, Xiaotian Zheng, Sameer J. Patel

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Transitioning from administration of monthly palivizumab to a single dose at discharge was associated with substantial pharmacy cost savings. With the concurrent adoption of private hospital rooms and visitor restriction policies, hospital-wide and neonatal intensive care unit healthcare-associated respiratory syncytial virus infections decreased following these changes. Infect Control Hosp Epidemiol 2018;39:485-487

Original languageEnglish (US)
Pages (from-to)485-487
Number of pages3
JournalInfection Control and Hospital Epidemiology
Volume39
Issue number4
DOIs
StatePublished - Apr 1 2018

ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Safety of Palivizumab Stewardship in Conjunction with Infection Prevention and Control Strategies for Healthcare-Associated Respiratory Syncytial Virus Infections'. Together they form a unique fingerprint.

Cite this